Neos Therapeutics Inc. (NEOS) Shares Down 3.8%
Neos Therapeutics Inc. (NASDAQ:NEOS) dropped 3.8% during trading on Thursday . The stock traded as low as $8.70 and last traded at $8.76, with a volume of 56,036 shares traded. The stock had previously closed at $9.11.
NEOS has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Thursday, April 21st. BMO Capital Markets reiterated a “buy” rating and set a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, July 19th. Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. Finally, Royal Bank Of Canada cut their target price on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Neos Therapeutics currently has an average rating of “Buy” and a consensus target price of $21.75.
The stock has a 50-day moving average price of $9.22 and a 200 day moving average price of $9.76. The stock’s market cap is $141.68 million.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.08. Analysts forecast that Neos Therapeutics Inc. will post ($4.88) earnings per share for the current fiscal year.
In other news, Director Gregory J. Robitaille purchased 7,442 shares of the stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average cost of $7.55 per share, with a total value of $56,187.10. Following the completion of the acquisition, the director now owns 55,677 shares in the company, valued at approximately $420,361.35. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Alan L. Heller purchased 10,000 shares of the stock in a transaction dated Thursday, May 19th. The stock was purchased at an average cost of $7.61 per share, for a total transaction of $76,100.00. Following the completion of the acquisition, the director now owns 379,888 shares of the company’s stock, valued at approximately $2,890,947.68. The disclosure for this purchase can be found here.
A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP increased its stake in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent SEC filing.
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.